Last reviewed · How we verify
MP-424
MP-424 is a hepatitis C virus (HCV) NS3/4A protease inhibitor that blocks viral replication by preventing the cleavage of viral polyproteins.
MP-424 is a hepatitis C virus (HCV) NS3/4A protease inhibitor that blocks viral replication by preventing the cleavage of viral polyproteins. Used for Chronic hepatitis C virus infection.
At a glance
| Generic name | MP-424 |
|---|---|
| Also known as | Telaprevir |
| Sponsor | Tanabe Pharma Corporation |
| Drug class | HCV NS3/4A protease inhibitor |
| Target | HCV NS3/4A protease |
| Modality | Small molecule |
| Therapeutic area | Virology/Hepatology |
| Phase | Phase 3 |
Mechanism of action
MP-424 binds to and inhibits the HCV NS3/4A serine protease, an enzyme essential for processing the HCV polyprotein into functional viral proteins. By blocking this protease activity, the drug prevents viral replication and reduces HCV viral load in infected patients. This mechanism is part of direct-acting antiviral (DAA) therapy for chronic hepatitis C.
Approved indications
- Chronic hepatitis C virus infection
Common side effects
- Nausea
- Headache
- Fatigue
- Diarrhea
Key clinical trials
- Efficacy and Safety of MP-424, Peginterferon Alfa-2b and Ribavirin in Relapser Genotype 2 Hepatitis C Infected Patients (PHASE3)
- Efficacy and Safety of MP-424, Interferon Beta (IFN Beta), and Ribavirin(RBV) in Treatment-Naïve or Having Received Interferon Based Therapy With Chronic Hepatitis C (CHC) (PHASE3)
- A Phase 1 Study of MP-424, Peginterferon Alfa 2b, and Ribavirin in Hepatitis C (PHASE1)
- Efficacy and Safety of MP-424, Peginterferon Alfa-2b, and Ribavirin in Patients With Chronic Hepatitis C Who Relapsed After Previous Interferon Based Therapy (PHASE3)
- Safety and PK Study of MP-424 to Treat Chronic Hepatitis C (PHASE1)
- Efficacy and Safety of MP-424/Peginterferon Alfa-2b/Ribavirin Combination in Treatment-Naïve Patients With Chronic Hepatitis C (PHASE3)
- Efficacy and Safety of MP-424, Peginterferon Alfa-2b and Ribavirin in Chronic Hepatitis C Who Have Not Achieved an Undetectable HCV RNA Level With Previous Interferon Based Therapy (PHASE3)
- Safety and Efficacy of MP-424 to Treat Chronic Hepatitis C (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |